Cargando…

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer

Our ability to detect and directly target the oncogenic alterations responsible for tumor proliferation has contributed significantly to the management of lung cancer in the last decade. The therapeutic efficacy of molecularly targeted therapy is, however, mainly limited to patients harboring certai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spaans, Johanna N., Goss, Glenwood D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107955/ https://www.ncbi.nlm.nih.gov/pubmed/25101246 http://dx.doi.org/10.3389/fonc.2014.00190

Ejemplares similares

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
por: Spaans, Johanna N., et al.
Publicado: (2014)

Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
por: Kong, Fanming, et al.
Publicado: (2021)

The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
por: Holder, Jessica E., et al.
Publicado: (2023)

The emerging role of circular RNAs in drug resistance of non-small cell lung cancer
por: Yan, Tinghao, et al.
Publicado: (2022)

The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
por: Saarenheimo, Jatta, et al.
Publicado: (2019)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Novel Nanoparticle-Based Cancer Treatment, Effectively Inhibits Lung Metastases and Improves Survival in a Murine Breast Cancer Model
por: Kraus, Sarah, et al.
Publicado: (2021)

Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic
por: Goss, Glenwood D., et al.
Publicado: (2022)

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
por: Zhu, Xiaoxi, et al.
Publicado: (2021)

The Molecular Role of IL-35 in Non-Small Cell Lung Cancer
por: Hao, Yuqiu, et al.
Publicado: (2022)

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer
por: Rybinski, Brad, et al.
Publicado: (2020)

The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer
por: Orlov-Slavu, Maria Cristina, et al.
Publicado: (2021)

Gene-Guided Treatment Decision-Making in Non-Small Cell Lung Cancer – A Systematic Review
por: Saarenheimo, Jatta, et al.
Publicado: (2021)

Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy
por: Wang, Wei, et al.
Publicado: (2022)

Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer
por: Wang, Yizhe, et al.
Publicado: (2021)

Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
por: Jain, Anisha S., et al.
Publicado: (2021)

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
por: Goss, Glenwood D., et al.
Publicado: (2016)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

Corrigendum: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
por: Jain, Anisha S., et al.
Publicado: (2021)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions
por: Hartgerink, Dianne, et al.
Publicado: (2018)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
por: Imyanitov, Evgeny N., et al.
Publicado: (2020)

Hippocampal Metastasis Rate Based on Non-Small Lung Cancer TNM Stage and Molecular Markers
por: Ahn, Sung Jun, et al.
Publicado: (2022)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
por: Gemelli, Maria, et al.
Publicado: (2022)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019
por: Chu, Xuetong, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer
por: Chicas-Sett, Rodolfo, et al.
Publicado: (2023)

The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer
por: Wong, Annick
Publicado: (2017)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
por: Tartarone, Alfredo, et al.
Publicado: (2021)

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis
por: Peng, Lu, et al.
Publicado: (2021)

The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
por: Billena, Cole, et al.
Publicado: (2023)

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity
por: van den Broek, Daan, et al.
Publicado: (2020)

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6mkpd4ailb3d5cr3es2h30ro26